Skip to main content

Table 1 Demographics, treatment, characteristics of breast and ovarian tumors, and disease outcome of the sixteen patients

From: A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer

  

Breast tumor

Ovarian tumor

 

Case #

BRCA status

Age at diagnosis

Stage

Local treatment

Systemic treatment

Age at diagnosis

Time interval from BC (months)

FIGO stage

Metastatic site

Outcome

1

ND

45

III

M

CT-T

48

34

IV

Liver

DOD

2

ND

48

III

M

CT

48

73*

IV

Liver

DOD

3

ND

45

III

BCS

CT-T

57

150

IV

Bone, liver

DOD

4

ND

59

I

BCS

No

70

130

IV

Peritoneal carcinomatosis, axillary LN

DOD

5

ND

57

III

M

T

58

20

IIIc

NA

DOD

6

ND

49

III

M

CT-T

52

33

IIIc

NA

DOD

7

BRCA2 m

66

I

BCS

CT

67

19

Ic

NA

NED

8

BRCA1 wt, BRCA2 uk

46

III

BCS

CT-T

46

0

IIa

NA

DOD

9

ND

34

III

M

CT-T

45

133

IV

Peritoneal carcinomatosis, supraclavicular LN, brain

SD

10

ND

47

III

M

T

54

83

IIIc

NA

NED

11

BRCA1 m

69

III

M

CT

71

24

IIa

NA

DOD

12

Familial history ¤

47

III

M

CT-T

54

79

IIIc

NA

DOD

13

ND

50

I

BCS

No

57

87

IIc

NA

NED

14

ND

57

II

BCS

T

64

82

IIc

NA

NED

15

BRCA1 wt, BRCA2 wt

32

III

M

CT

38

74

IV

Pleura

DOD

16

ND

48

II

BCS

CT

49

18

IIIc

NA

DOD

  1. BRCA: BReast CAncer gene, ND = not determined; m = mutation; wt = wild type; uk = unknown; M = mastectomy; BCS = breast-conserving surgery; CT = chemotherapy; T = tamoxifen; BC = breast cancer; LN = lymph nodes; NA = not applicable; DOD = died of disease; NED = no evidence of disease; SD = stable disease.
  2. * Patient who developed simultaneously ipsilateral breast cancer relapse and ovarian tumor.
  3. ¤ Her mother had a c.669A > G/Gln147GIN variation in the BRCA2 gene.